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Abstract 
The gene B-Raf proto-oncogene serine/threonine kinase (BRAF) is the most frequently mutated 
gene in malignant melanoma (MM) and is causally involved in melanoma and papillary thyroid 
cancer (PTC) carcinogenesis. Mutated BRAF is associated with an aggressive disease phenotype, 
thus making it a top candidate for targeted treatment strategies in MM and PTC patients. We 
show that mutations in BRAF in both MM and PTC lead to increased expression of a small non-
coding RNA, miR-3151. Reducing miR-3151 expression decreases cell viability and increases 
apoptosis rates in MM and PTC. Thus, miR-3151 may be a novel downstream effector of 
mutated BRAF, which contributes to the aggressive phenotype associated with BRAF mutations. 
Using a targeted RNA sequencing approach we determined that miR-3151 directly targets TP53 
and other members of the TP53 pathway. As determined by confocal microscopy and nuclear 
fractionation, knock-down of miR-3151 in MM and PTC cells increased TP53 expression and 
also favored its nuclear localization. To determine whether targeted knock-down of miR-3151 
may have therapeutic potential in MM and PTC, we tested whether a simultaneous treatment of 
MM and PTC cells with the FDA-approved BRAF inhibiting drug vemurafenib and knock-down 
of miR-3151 with a small hairpin RNA would add on to the effects of sole BRAF inhibition. 
Indeed, combined inhibition of mutated BRAF and miR-3151 significantly increased cell death 
and lowered the dose of vemurafenib required to achieve the observed effects. Taken together, 
we suggest miR-3151 as a novel player in BRAF mutated malignancies, which acts by direct 
targeting of the tumor suppressor TP53 and several of its pathway members. Targeted knock-
down of miR-3151 may increase the effectiveness of sole BRAF inhibition in MM and PTC.  
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Introduction 
Malignant Melanoma 
The incidence rate of malignant melanoma (MM), a cancer of melanocytes, has dramatically 
increased within the last decades, with an estimated 76,100 new cases reported in 2014
1
. 
Melanoma is the fifth most common type of cancer in the U.S
1
. Malignant melanoma occurs 
when damaged DNA generates oncogenic mutations within the skin cells. This damage is most 
often caused by exposure to ultraviolet radiation from the sun or tanning beds
2
. Malignant 
melanomas can be characterized into five basic stages, based on localization and invasiveness. 
The survival rates of melanoma depend on the stage of the cancer (Figure 1). Melanomas that are 
restricted to their primary sites, or localized, have the highest rates of survival, while melanomas 
that have spread to nearby lymph nodes are deemed regional
1
. Metastatic melanomas are distant 
and have the lowest rates of survival
1
. Despite extensive research, metastatic malignant 
melanomas have one of the poorest survival rates of all human cancers.  
 
 
Figure 1. Survival rate of melanoma cases based on 
stage. When the cancer becomes metastatic (distant), the 
survival rate decreases dramatically.  
From “SEER Stat Fact Sheets: Melanoma of the Skin”1. 
 
 
Papillary Thyroid Cancer 
Papillary thyroid cancer (PTC) is the most common type of thyroid cancer, accounting for 80% 
of all thyroid cancers
3
. Incidence rates of PTC are rapidly growing, with over 20,000 new cases 
5-Year Relative Survival of Melanoma Cases 
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reported each year
3
. Predominantly, cases of PTC occur with no apparent risk factors, although 
radiation exposure and a family history of PTC can predispose an individual
3
. Fortunately, PTC 
is the type of thyroid cancer with the highest survival rate and, in contrast to MM, prognosis does 
not deteriorate as severely with metastasis and invasion. Localized and regional PTCs have 
comparable rates of survival, and distant PTCs have a lower, but still favorable, prognosis
3
 
(Figure 2).  
 
 
Figure 2. Survival rates of thyroid cancer cases 
based on stage. Survival rates of PTC are high when 
localized and regional. When the cancer becomes 
distant, prognosis remains favorable. 
From “SEER Stat Fact Sheets: Thyroid Cancer”3. 
 
 
B-Raf proto-oncogene serine/threonine kinase (BRAF) 
Despite the stark differences between MM and PTC in their disease aggressiveness, treatment 
strategies, and prognosis, there is at least one molecular feature that is shared by both 
malignancies – frequent mutations in the oncogenic tyrosine kinase B-Raf proto-oncogene 
serine/threonine kinase (BRAF). BRAF is part of the RAS/MAPK pathway, which is involved in 
many important cellular functions, including proliferation, differentiation, migration, and 
apoptosis
4
. BRAF is most frequently mutated to a constitutively active form (V600E) in many 
cancers, including MM (~60%) and PTC (~44%)
1, 5
. When mutated, BRAF is associated with a 
more aggressive disease phenotype in MM and PTC
2, 7
. Direct inhibition of aberrantly activated 
5-Year Relative Survival of Thyroid Cases 
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BRAF (e.g, with an FDA approved drug, vemurafenib) has shown some effectiveness, but only 
in a subset of patients and with the eventual development of resistance in most cases
8
. 
Tumor protein p53 (TP53) 
Additionally, the inactivation of the tumor suppressor gene tumor protein p53 (TP53) is a 
common event in many MMs
9
, as well as a multitude of other human cancers. TP53 is an 
essential tumor suppressor through its regulation of cell proliferation and apoptosis. Upon 
cellular stress, TP53 activates one of two pathways, either promoting DNA repair to continue on 
to the cell cycle or signaling apoptosis (Figure 3). Pharmacologic restoration of TP53 activity, in 
combination with BRAF inhibition, represents a promising treatment strategy in MM, and will 
likely have a potential for a much broader spectrum of patients once agents with higher 
effectiveness have been identified
10, 11
. Therefore, a better understanding of the deregulated 
downstream signaling of BRAF and the inactivation of TP53 are major challenges in MM 
research.  
 
Figure 3. The TP53 pathway. In response to cellular 
stress or DNA damage, TP53 activates either a 
pathway for cell cycle arrest and DNA repair or 
apoptosis.  
From “Apoptosis signaling pathway - @ a glance”, 
Abcam.com43. 
 
 
Although inactivating mutations in TP53 are found only in 10% of thyroid cancer cases, they are 
mainly found in poorly differentiated and aggressive tumors
12
. Poorly differentiated tumors lack 
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normal tissue structures and are comprised of cells with abnormal morphology that poorly 
resemble the tissue of origin
13
. These tumors typically grow faster and are more likely to spread 
than well-differentiated tumors
13
. Thus, reviving TP53 expression could be a possible treatment 
strategy for this small subset of particularly aggressive tumors.  
MicroRNAs 
MicroRNAs (miRs) are small, non-coding RNAs, normally 19-26 nucleotides in length, that 
downregulate the expression of their target gene
14
. miRs downregulate their target genes by the 
binding of the seed sequence of the miR to the complementary sequence in the 3’ UTR of the 
target gene (Figure 4). miRs downregulate expression through a variety of mechanisms, 
including inhibiting translation and promoting mRNA degradation. Their target genes vary in 
different cell and tissue types and potentially regulate a specific pathway through simultaneous 
regulation of multiple genes. miRs have been associated not only in normal biological process, 
such as cell proliferation, differentiation, and survival, but also in human disease
15, 16, 17, 18
. 
Deregulation of specific miRs has been implicated in the disease initiation and progression of 
virtually every human cancer, including MM
14
.  
 
 
 
 
 
 
Figure 4: Gene expression of target gene with and without the microRNA. microRNAs bind to their 
complementary sequence in the 3’ UTR of the target gene to downregulate gene expression via various mechanisms. 
Gene 
5’ 3’ 
Gene Product 
TCCGAGA 
AGGCTCT 
Gene 
5’ 3’ 
Gene Product 
Without microRNA: 
With microRNA: 
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Intronic miRs 
Although microRNAs can be found throughout the genome, approximately one third of 
mammalian miRs are located within the introns of their host genes
19, 20
. While some miRs are 
thought to be co-expressed from the same precursor mRNA in which they reside
21, 22
, about 26% 
of intronic miRs possess their own promoters and can be transcribed as independent units
23, 24, 25
. 
However, the functional relationship between miRs and their hosts is still largely unknown. 
Many intronic miRs are believed to strengthen the function of their host genes, either directly by 
targeting genes within the same cellular pathway
26, 27
 or indirectly through silencing genes 
antagonistic to their hosts
28
. Furthermore, miRs could be shown to be responsible for effects 
originally contributed to their host genes, and these effects can be attained through expression 
independent of the host gene
29
.  
microRNA-3151 
Recently, intronic microRNA miR-3151 was identified in intron 1 of the gene brain and acute 
leukemia, cytoplasmic (BAALC) via deep-sequencing of MM samples. In acute myeloid leukemia 
(AML), high expression of miR-3151 is associated with poor survival of patients and displays 
direct leukemogenic activity via deregulation of TP53 and several TP53 pathway members
30, 31
. 
First evidence exists that miR-3151 can downregulate TP53 and decrease apoptosis in MM as 
well
30
. Additionally, the expression of miR-3151 was found to be deregulated in many MM 
patients, with BRAF mutated (BRAFmut) tumors having a 5-fold higher expression of miR-3151 
when compared to BRAF wild-type (BRAFwt) tumors
30
. Thus, we hypothesized that further 
elucidation of miR-3151’s role in MM, and specifically, its connection with BRAF mutations and 
TP53, may provide novel insights into melanogenesis, increase our understanding of the BRAF 
mutant downstream biology, and enhance our options for therapeutic interventions. Furthermore, 
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we hypothesized that the novel link between BRAF mutations, miR-3151 and TP53 may also 
apply to other BRAF mutated malignancies such PTC. 
Here we tested the above hypothesis by studying the effects of miR-3151 and its knock-down in 
MM and PTC cells treated or untreated with vemurafenib, a drug used in the therapy of patients 
with BRAF-mutated MM. We investigated the BRAF-dependent and –independent regulatory 
mechanisms of miR-3151. We identified the TP53 pathway as a target of miR-3151 and speculate 
that the combined use of BRAFmut inhibitors and knocking down miR-3151 may become a 
treatment option in patients with BRAF-mutated tumors.   
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Statement of significance 
MM has one of the poorest survival rates of all human malignancies, despite extensive research. 
BRAF mutations are the most common genetic events in MM and PTC, and are associated with a 
more aggressive disease phenotype. Additionally, low expression of TP53 is seen in most cases 
of MM, and is considered a key element of the disease. miR-3151 was identified as a novel 
player in MM and PTC pathogenesis and is driven by BRAF-dependent and -independent 
mechanisms. Characterization of TP53 as a downstream effector of miR-3151 provides first 
evidence for a causal link between BRAF mutations and TP53 inactivation. Based on our results, 
we propose to use the combined inhibition of mutated BRAF and miR-3151 as a target in BRAF 
mutated human malignancies.  
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Results   
 
AntagomiR-3151 activates the TP53 pathway in malignant melanoma and increases the 
nuclear localization of TP53. 
When assessing miR-3151 in a broader cohort of human cancer samples we recently discovered 
that miR-3151 levels were 5-fold higher in melanoma primary tumors with an activating 
mutation in the BRAF kinase gene compared to tumors with wild-type BRAF
30
. Pilot experiments 
gave first evidence of TP53 as a possible downstream target of miR-3151 in MM cells
30
, which, 
of note, is inactivated in the majority of MM tumors. These results open the opportunity to tie the 
presence of BRAF mutations to the known low TP53 expression levels of melanoma cells via 
miR-3151. 
To strengthen the evidence that miR-3151 is an important regulator of TP53 expression in MM 
in vivo, we determined miR-3151 and TP53 expression in the tumors of a cohort of MM patients 
(n=21) and assessed a possible association of the expression levels of the two genes. Patients 
with high expression of miR-3151 tended to have lower expression of TP53 and vice versa 
(Figure 5).  
Figure 5. miR-3151 in MM. TP53 expression in 
high miR-3151 and low miR-3151 expressing MM 
patients, *, P<0.05, two-tailed t test. 
 
 
 
 
Next, to explore miR-3151’s effects on TP53 and its pathway members in MM, we took a broad 
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screening approach for the identification of possible target genes. Using the TruSeq RNA 
platform (Illumina), we custom designed a panel of 361 genes and tested the effects of forced 
miR-3151 expression and miR-3151 knock-down on the mRNA levels of the panel genes in Mel-
39 MM cells.  A total of 34 genes showed ≥20% downregulation of their mRNA expression by 
miR-3151 and concordant ≥20% upregulation by antagomiR-3151 compared to scramble. 
Therefore these genes were considered as potential direct miR-3151 targets (Figure 6). In 
addition, 24 genes showed concordant ≥20% upregulation by miR-3151 and downregulation by 
antagomiR-3151 (Figure 6), suggesting indirect regulatory mechanisms.  
As expected, TP53 was downregulated by forced miR-3151 expression and upregulated by 
antagomiR-3151 (Figure 6). In addition, several of its pathway members were also 
downregulated, including BCL2, RBL2, CASP1, CASP9, MAP3K4, and CDK1 (Figure 6). Eleven 
of the 34 downregulated genes were predicted to harbor at least 1 binding site for miR-3151 in 
their 3′-UTR and therefore may be potential direct miR-3151 targets (Table 1).  
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Figure 6. Direct and indirect targets of miR-3151. 
Heatmap of gene expression changes concordantly 
affected by forced miR-3151 expression or miR-3151 
knock-down based on targeted RNA sequencing. 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Potential direct target genes of miR-3151. Genes which showed concordant ≥20% 
downregulation in their mRNA expression by miR-3151 and ≥20% upregulation by antagomiR-3151 in 
the RNA sequencing approach were considered potential direct miR-3151 targets. Their 3′-UTRs were 
tested for predicted miR-3151 binding sites using a computational prediction approach (microRNA.org). 
Listed are the genes with predicted miR-3151 binding sites including their affinity scores (miRSVR score 
and PhastCons score). 
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Gene 
 
Number of predicted 
binding sites 
mirSVR score 
 
PhastCons score 
 
BIK     1    -0.1048     0.5207 
CARD6 1 -0.0107 0.6 
NFATC1 1 -0.0006 0.3967 
TP53 2 -0.003 0.648 
  -0.0063 0.4148 
SP1 2 -0.0041 0.653 
  -0.0022 0.6501 
MCL1     2    -0.0011     0.4804 
  -0.2373 0.6276 
NOL3 1 -0.0093 0.5414 
NRAS 2 -0.0023 0.5623 
  -0.0036 0.5216 
ANAPC2 1 -0.0026 0.475 
FGFR1 1 -0.0018 0.5134 
HOOK3 1 -0.0038 0.5079 
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To gain first insights into the pathways affected by miR-3151, we performed a pathway analysis 
of the up- and downregulated genes (n=58) using the Ingenuity platform. The top scoring 
molecular and cellular functions affected by miR-3151 were Cell Death and Survival, Cellular 
Growth and Proliferation, and Cell Cycle (Table 2). 
 
Table 2. Molecular and Cellular Functions predicted to be influenced by miR-3151 (Ingenuity). Listed 
are the top ranking components of the Global Canonical Pathway Category (GCP) after pathway analysis 
(www.ingenuity.com, pathway names and involved molecules defined by Ingenuity) of the miR-3151 
associated gene expression signature. The P-value associated with a pathway in Global Canonical 
Pathways (GCP) is a measure of the likelihood that the association between a set of focus genes in the 
analyzed experiment and a given pathway is due to random chance. The P-value identifies statistically 
significant over-representation of focus genes in a given process. It is automatically calculated by the 
ingenuity.com program using the right-tailed Fisher Exact Test. 
 
Pathway name (Ingenuity) 
 
P-value Number of molecules 
Cell Death and Survival     4.12
-122
-1.38
-21 
   241 
Cellular Growth and Proliferation 1.85
-85
-1.2
-21 
   236 
Cell Cycle 1.42
-75
-9.3
-22 
   152 
Gene Expression 1.04
-72
-5.43
-32 
   176 
Cellular Development 1.65
-69
-1.2
-21 
   219 
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To distinguish between nuclear (transcriptionally active) TP53 and cytoplasmic TP53, we used 
cellular fractionation of Mel-39 cells after either stable introduction or knock-down of miR-3151 
compared to scramble control. AntagomiR-3151 led to a preferred nuclear localization of TP53 
(Figure 7A). We used confocal microscopy to validate the changes in the cellular localization 
caused by antagomiR-3151 in A375 and Mel-39 cells. The knock-down of miR-3151 
dramatically favored the nuclear localization of TP53, thereby suggesting an increased 
transcriptional potential of the tumor suppressor gene caused by antagomiR-3151 (Figure 7B). 
 
 
 
 
 
 
 
 
Figure 7. Cellular localization of TP53. A. Nuclear fractionation of Mel-39 cells after manipulation of 
miR-3151 expression to determine the favored cellular localization of TP53.B. Confocal imaging of 
TP53’s cellular localization in A375 and Mel-39 cells after manipulation of miR-3151 expression. 
A B 
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Targeted knock-down of miR-3151 increases apoptosis and reduces cell viability of MM 
cells. 
As our pilot experiments suggested an increase in caspase-3/7 activity caused by antagomiR-
3151
30
, we aimed to gain further evidence for a possible growth-limiting effect on MM cells, 
which may in part be mediated by the increased expression of TP53. We stably infected Mel-39 
and A375 cells with miR-3151, antagomiR-3151 or scramble control, and determined the cellular 
proliferation rate with chemiluminescent TiterGlo assays. While increasing the abundance of 
miR-3151 increased the proliferation of both cell lines compared to scramble control, 
antagomiR-3151 led to reduced proliferation (Figure 8).  
 
Figure 8. Proliferation rates in response to miR-
3151. Cell viability of A375 and Mel-39 cells after 
forced miR-3151 expression or knock-down in 
chemiluminescent assays. 3 experiments, bars, mean ± 
SD; *, P<0.05, **, P<0.005, two-tailed t test. 
 
 
 
 
The apparent decrease in growth by antagomiR-3151 could result from a decrease in the rate of 
cell division, an increase in apoptosis, or a combination of the two. To test whether the reduced 
TiterGlo activity is solely due to a lowered rate of cell division, or additionally potentiated by an 
increase in cell death and apoptosis, we performed a flow cytometric determination of Annexin-
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V and Annexin-PI in antagomiR-3151 infected Mel-39 cells. Indeed, knock-down of miR-3151 
increased the percentage of apoptotic cells (Figure 9) and also reduced the percentage of cells in 
both S-phase and G2-phase. Additionally, we used confocal microscopy to compare the 
expression and cellular localization of caspase-3, a major determinant of apoptotic activity. In 
line with the previous experiments, miR-3151 reduced caspase-3 expression, while antagomiR-
3151 increased caspase-3 expression (Figure 10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Changes in the cell cycle. Examples of changes in apoptosis and cell cycle in Mel-39 cells after 
miR-3151 knock-down. In the above two graphs, the red boxes indicate apoptotic cells or cells 
undergoing apoptosis. In the lower two graphs, the peak highlighted in green represents cells in the G1 
phase, the yellow peak is cells in S phase, and the blue peak is cells in G2 and M phases. 
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Figure 10. Caspase-3 cellular 
localization. Confocal imaging of 
caspase-3’s expression and cellular 
localization in A375 and Mel-39 cells 
after manipulation of miR-3151 
expression. 
 
 
 
 
 
 
 
 
miR-3151 expression can be increased by BRAF mutations and the SP1/NF-κB 
transactivating complex. 
As malignant melanoma samples with an activating BRAF mutation have a 5-fold higher 
expression of miR-3151 compared to BRAF wildtype (BRAFwt) samples
30
, we wanted to 
elucidate whether miR-3151 may be a direct downstream effector of aberrantly activated BRAF 
and contribute to the increased disease aggressiveness associated with BRAF mutations 
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(BRAFmut). If miR-3151 is downstream of BRAF, an introduction of the mutation into BRAFwt 
cells should increase miR-3151 expression and consequently lead to a further reduction of TP53, 
while knock-down of BRAFmut should reduce miR-3151’s abundance and elevate TP53 
expression. In line with our hypothesis, transfection of MeWo cells (BRAFwt) with a BRAFmut 
expression construct increased miR-3151 expression and reduced TP53 expression (Figure 11A). 
siRNA-mediated knock-down of BRAFmut in A375 and Mel-39 cells reduced miR-3151 
expression and increased TP53 at both the mRNA and protein levels (Figure 11B and 11C). 
 
Figure 11. Effects of BRAFmut on 
miR-3151 and TP53. A. Effects of 
BRAFmut on miR-3151 and TP53 
expression in BRAFwt MeWo cells. 3 
experiments, bars, mean ± SD; *, 
P<0.05, two-tailed t test. B. Effects of 
BRAF knock-down (si-BRAF) on 
miR-3151 and TP53 expression in 
BRAFmut A375 and Mel-39 cells. 3 
experiments, bars, mean ± SD; *, 
P<0.05,**, P<0.005, two-tailed t test. 
C. Example of miR-3151’s effects on 
TP53 protein expression. 
 
 
 
A 
B 
C 
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In AML, miR-3151 can be regulated by the SP1 transcription factor/ nuclear factor kappa-B 
(SP1/NF-κB) transactivating complex30, which binds to the regulatory region of miR-3151 (TSS-
3151). To test whether this activation also regulates miR-3151 in MM, we transfected A375, 
Mel-39 and MeWo cells with expression constructs for SP1 or NF-κB (p65). While A375 cells 
showed a greater response to SP1, Mel-39 cells reacted preferentially to transfection with NF-κB 
(Figure 12A). Finally, electrophoretic mobility shift assays with nuclear extracts harvested from 
both A375 and Mel-39 cells indicated a direct interaction of SP1/NF-κB with TSS-3151 (Figure 
12B). Thus, aberrant expression of miR-3151 in melanoma seems to be a combined effect of 
BRAFmut and transcriptional activation by the SP1/NF-κB transactivating complex.  
Figure 12. SP1/ NF-κB transactivating complex activates miR-3151 expression. A. Effects of SP1 and 
NF-ĸB on miR-3151 expression in A375 and Mel-39 cells. 3 experiments, bars, mean ± SD; *, 
P<0.05,**, P<0.005, two-tailed t test. B.  Visualization of SP1’s binding to miR-3151’s transcription start 
site (TSS-3151) using EMSA. Nuclear extracts (NE) used from A375 and Mel-39 cells, shifting 
performed with SP1-antibody (SP1-AB). 
 
A 
B 
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The BRAF-miR-3151-TP53 axis is also present in papillary thyroid cancer. 
In addition to MM, BRAF mutations are frequently found in papillary thyroid cancer (PTC)
32
 and 
are associated with a more aggressive disease phenotype
33
. To test whether the newly identified 
axis between BRAF mutations, miR-3151 expression and reduced TP53 levels is also present in 
PTC, we first determined the BRAF mutation status and the endogenous miR-3151 expression in 
a cohort of 16 PTC tumor samples. As seen in MM, patients with BRAFmut tumors had higher 
endogenous miR-3151 expression (Figure 13A). In addition, patients with higher miR-3151 
expression had lower endogenous TP53 expression levels (Figure 13B).  
 
Figure 13. miR-3151 in PTC. A. Endogenous miR-3151 expression levels in tumor samples of BRAFwt 
and BRAFmut PTC patients. *, P<0.05, two-tailed t test. B. Endogenous TP53 expression of low miR-
3151 and high miR-3151 expressing PTC patients. *, P<0.05, two-tailed t test. 
 
 
To validate that miR-3151 affects TP53 expression, we stably introduced miR-3151 into two 
A B 
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PTC cell lines (KTC1 and BCPAP). Forced miR-3151 expression reduced TP53 at both the 
mRNA and protein levels (Figure 14A). Confocal microscopy of the cell lines showed a 
reduction of TP53 messenger expression and also a reduced nuclear localization of the protein, 
while antagomiR-3151 strongly enhanced the expression and nuclear localization of TP53 
(Figure 10B). The changes in TP53 expression also changed the expression levels of caspase-3 
indicating that knock-down of miR-3151 enhances cell death also in PTC (Figure 14B). 
Figure 14. miR-3151’s effects on TP53 and Caspase-3 in 
PTC. A. Effects of forced miR-3151 expression on TP53 
mRNA and protein levels in KTC1 and BCPAP cells. 3 
experiments, bars, mean ± SD; *, P<0.05, two-tailed t test. 
B. Confocal imaging of TP53’s and caspase-3’s expression 
and cellular localization in A375 and Mel-39 cells after 
manipulation of miR-3151 expression. 
 
 
 
 
 
 
 
 
 
 
A 
B 
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This was further supported by TiterGlo assays, which showed decreased viability in cells 
infected with antagomiR-3151 (Figure 15). Finally, the effects of BRAFmut knock-down on 
miR-3151 expression (Figure 16) and the transcriptional activation of miR-3151 by the SP1/NF-
ĸB complex were also validated in PTC cells (Figure 17). 
 
Figure 15. miR-3151 effects on cell viability in PTC. Cell viability of KTC1 
cells after knock-down of miR-3151. 3 experiments, bars, mean ± SD; *, 
P<0.05, two-tailed t test.  
 
 
 
Figure 16. BRAFmut effects miR-3151 in PTC. Effects of BRAF 
knock-down (si-BRAF) on miR-3151 expression and TP53 expression in 
KTC1 and BCPAP cells. 3 experiments, bars, mean ± SD; *, P<0.05,**, 
P<0.005, two-tailed t test.  
 
 
Figure 17. SP1/ NF-ĸB activation of miR-3151 in PTC. Effects of SP1 
and NF-ĸB on miR-3151 expression in KTC1 and BCPAP cells. 3 
experiments, bars, mean ± SD; *, P<0.05,**, P<0.005, two-tailed t test. 
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Knock-down of miR-3151 and BRAFmut in MM and PTC cells increases sensitivity to 
vemurafenib treatment. 
Even though we identified miR-3151 as a new downstream effector of BRAF, it is only one of 
many known BRAF targets. Perhaps the most important known genes affected by aberrantly 
activated BRAF are the mitogen-activated protein kinase kinase 7 (MEK) and the mitogen-
activated protein kinase 1 (ERK), which facilitate signal transduction and ultimately lead to 
increased gene transcription and translation
34
. Of note, above we demonstrated that miR-3151 is 
not only activated by BRAF, but also by the SP1/NF-κB transactivation complex. Thus, to most 
effectively disrupt both pathways, simultaneous inhibition of BRAFmut (to stop activation of the 
MEK/ERK cascade and also reduce miR-3151 expression) and targeting of miR-3151 (to stop its 
activation by SP1/NF-κB), either by proteasome inhibitors to limit SP1/NF-κB’s binding 
activity, or by direct miR-3151 inhibition with antagomiR-3151, may be an interesting combined 
treatment approach (Figure 18).  
 
 
Figure 18. Schematic depiction of 
the proposed BRAF-miR-3151-
TP53 axis. Simultaneous inhibition 
of BRAF (via BRAF inhibitors) and 
miR-3151 (shown here through 
antagomiR-3151) could be a possible 
treatment method. 
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As a proof-of-principle, we first tested the effects of the BRAF inhibitor vemurafenib on miR-
3151 expression. Indeed, treatment of BRAFmut Mel-39 (MM) and KTC1 cells (PTC) led to a 
modest reduction of miR-3151 expression (Figure 19).  
  
 
 
 
 
 
 
 
Figure 19. Vemurafenib treatment of MM and PTC cells. Effects of vemurafenib treatment on miR-
3151 expression in Mel-39 (1.0 μM vemurafenib) and KTC1 cells (1.4 μM vemurafenib) compared to 
vehicle. 3 experiments, bars, mean ± SD.  
Next, we used stably miR-3151 and antagomiR-3151 expressing Mel-39 and KTC1 cells for 
vemurafenib treatment and compared their response to cells infected with scramble control. 
While treatment with 1.0 μM  (Mel-39) and 1.4 μM (KTC1) vemurafenib had no effect on cell 
proliferation in miR-3151 infected cells, it reduced the growth in scramble-infected cells and 
killed all cells with antagomiR-3151 (Figure 20). Finally, we created a vemurafenib-resistant 
A375 cell line and compared the endogenous miR-3151 expression level to the parental (non-
resistant) A375 cells. The vemurafenib-resistant A375 cells had a 35-fold higher endogenous 
miR-3151 expression (Figure 21). Taken together, these pilot experiments may encourage in vivo 
tests of this combined targeted treatment approach. 
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Figure 20. Images after vemurafenib treatment. Depiction of the differential effect of vemurafenib 
treatment on Mel-39 and KTC1 cells after forced miR-3151 expression or knock-down.  
 
 
 
Figure 21. Effect of vemurafenib resistance on miR-3151. 
Changes in miR-3151 expression after development of 
vemurafenib resistance (A375 vem. res.) compared to the 
parental cell line (A375 vem. sens.). Resistant A375 cells 
are long-term cultured in 2 μM vemurafenib. 3 experiments, 
bars, mean ± SD; *, P<0.05, two-tailed t test.  
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Discussion 
 
MM is the most deadly skin cancer, accounting for 75% of all skin cancer deaths with numbers 
continuously increasing
1
. When diagnosed at an advanced stage (stage IV), the 5-year survival 
rates of the patients are only ~15%
1
, underlining the urgent need for better treatment options for 
advanced stage patients. BRAF mutations are the most frequent mutations in MM and are 
associated with increased disease aggressiveness
6
. Therefore, targeting BRAF has become one of 
the most promising treatment options in BRAF mutated MM patients
8
. Still, many questions 
regarding the downstream signaling of mutated BRAF remain unanswered.  
As a second crucial event, the tumor suppressor TP53 is downregulated in almost all MM, but the 
reasons are not fully understood
9
. Restoration of TP53 activity represents an important treatment 
strategy in MM
10
. The BRAF mutation and repression of TP53 are important events in melanoma 
progression. In fact, disruption of the TP53 pathway via short hairpin RNA in benign nevi with 
BRAF mutations may promote malignant transformation of the cells
11
. Thus, the identification of a 
causal link between these two important players (BRAF and TP53) would increase our 
understanding of MM pathophysiology. 
Vemurafenib is an orally administered, small molecule selective BRAF inhibitor approved by the 
FDA for the treatment of unresectable or metastatic MM with presence of the BRAF V600E 
mutation
35
. In an international multicenter trial (NCT01006980), treatment with vemurafenib was 
superior to treatment with chemotherapy (dacarbazine)
36
. However, not all patients benefited from 
treatment with vemurafenib
36, 37
. 
Deregulation of specific miRs has been implicated in the disease initiation and progression of 
virtually every human cancer
38, 39
, including MM
40
. Specific targeting of aberrantly activated 
miRs, either indirectly via blockage of their upstream activation or direct via antagomiRs, 
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represents a promising new therapeutic approach
41, 42
. 
We have shown that miR-3151 is upregulated in BRAFmut MM and have provided the first 
evidence that miR-3151 leads to reduced MM cell growth by direct downregulation of its target 
TP53. We propose that miR-3151 may be a crucial link between BRAF mutations and the observed 
downregulation of TP53. 
Additional upregulation of miR-3151 by BRAF-independent mechanisms (SP1/NF-κB 
transactivating complex) may explain why some patients show tumor progression under 
vemurafenib treatment, and may be an alert to combine vemurafenib with other 
chemotherapeutics. 
Determination of miR-3151 and TP53 expression in BRAFmut MM tumors during vemurafenib 
therapy will provide insight into the predictive value of miR-3151 expression. Connecting BRAF 
mutations with TP53 downregulation via increased expression of miR-3151 is a testable approach 
in MM research. Further elucidation of the mechanism by which BRAFmut upregulates miR-3151 
will increase our understanding of the BRAF mutant downstream biology and enhance our options 
for therapeutic interventions.  
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Materials and Methods 
Patient samples  
PTC samples (n=16) were obtained from the Human Cancer Genetics Tissue Bank at OSU. All 
patients provided written informed consent according to the Declaration of Helsinki to store and 
use their tissue for discovery studies according to OSU institutional guidelines under protocols 
approved by the OSU Institutional Review Board. Total RNA samples from MM patients (n=21) 
were purchased from Asterand.  
Tissue culture experiments  
For studying miR-3151 in MM A375, Mel-39 and MeWo cells were provided by the laboratory 
of W.E. Carson. Cells were cultured in DMEM medium supplemented with 10% Fetal Bovine 
Serum (FBS) and 1% Antibiotic-Antimycotic (Gibco). For studying miR-3151 in PTC, KTC1 
and BCPAP cells were obtained from the American Type Culture Collection (ATCC). Cells were 
cultured in RPMI medium supplemented with 10% Fetal Bovine Serum (FBS) and 1% 
Antibiotic-Antimycotic (Gibco).  
To create vemurafenib resistant A375 cells, the cells were cultured in increasing concentrations 
of vemurafenib (0-10 μM) over a period of 8 weeks with 2-fold dosage increases once a week. 
After confirmation of resistance using MTT assays, the cells were cultured in 2 μM vemurafenib. 
Overexpression of miR-3151 and miR-3151 knockdown 
For stable expression, the stem loop of miR-3151 with 200 bp flanking sequence was cloned into 
an HIV-based lentiviral dual promoter vector as previously described (pCDH-CMV-MCS-EF1-
copGFP+Puro cDNA; System Biosciences). For targeted knock down of miR-3151, a custom-
made antagomiR-3151 was purchased from System Biosciences. As a control, lentiviral scramble 
miR was used according to the manufacturer’s instructions (miRZiP000, System Biosciences). 
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Lentiviral construct (4500 μg) was transfected into 293TN cells using 45 μg pPACKH1 and 55 
μl PureFection (System Biosciences). After 48h and 72h the supernatant containing the 
pseudoviral particles was collected and the virus precipitated overnight at 4°C using 5 ml PEG-
IT virus precipitation solution (System Biosciences). We used 200 μl Phosphate Buffered Saline 
and 25 μM Hepes Buffer for resuspension of the pelleted virus. We infected 200,000 cells/ml in 
triplicate with 20 IU virus, using 5 μl Transdux Infection Reagent (System Biosciences).  
cDNA synthesis and miR-3151 mRNA analysis 
To check for successful overexpression of miR-3151 and to analyze the effect of forced miR-
3151 expression on the predicted target genes, RNA from 1 million cells was harvested on day 
14 after infection and reverse transcribed to cDNA using the TaqMan MicroRNA Reverse 
Transcription Kit (Life Technologies Corporation/Applied Biosystems) or the Superscript III 
First-Strand cDNA Synthesis Kit (Life Technologies Corporation/Invitrogen). Both kits were 
used according to the manufacturer’s instructions. miR-3151 abundance was determined by qRT-
PCR as previously described (21). Simultaneously protein (from 4 million cells) was harvested 
and used for Western blotting.  
Transient overexpression of BRAFwt, BRAFmut, SP1 and NF-κB 
For transient overexpression, 3 μg of the overexpression constructs of BRAFwt, BRAFmut, SP1, 
NF-κB and (all cloned in pIRES2-EGFP vector, Clontech) or the p65 subunit of NF-κB (cloned 
as pCMV-p65) were transfected in triplicate into 3 million Mel-39 and A375 cells using 
Purefection transfection reagent according to the manufacturer’s instructions (System 
Biosciences).  
TruSeq targeted RNA analysis 
A customized Add-on panel comprised of 361 genes using the backbone of the Illumina 
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apoptosis panel and the Illumina stem cell panel was designed using DesignStudio (Illumina) for 
the TruSeq Targeted RNA expression analysis. Library preparations using 100 ng total RNA 
(miR-3151+scramble: harvest 3h post transfection, antagomiR-3151/scramble: harvest 24h post 
transfection) and the Miseq run were performed according to the manufacturer’s instructions. 
MiSeqReporter software was used to estimate target hits for each transcript after aligning reads 
against references specified by Targeted Oligo Pool, using banded Smith-Waterman alignment. 
The raw count data was then normalized using the R library DESeq (V 1.14.0), built based on 
negative binomial distribution, with variance and mean linked by local regression (20). Percent 
relative changes of mRNA expression of miR-3151 and antagomiR-3151 compared to scramble 
were estimated. 
TiterGlo assays 
Cell viability changes in Mel-39, A375 and KTC1 cell lines infected with lentiviral miR-3151, 
antagomiR-3151, or scramble control were analyzed using the Titer Glo assay (Promega) 72h 
after Puromycin selection using 20,000 cells in duplicate of three biological replicates according 
to the manufacturer’s instructions.  
Western blotting assays 
Western blotting was performed according to standard procedures. Antibodies used were p53 
(#sc-126, Santa Cruz), Caspase-3 (#9665S, Cell Signaling), Actin (#sc-1616, Santa Cruz). 
Confocal microscopy 
Confocal staining was performed by standard procedures using the following antibodies: p53 
Ab-2 (Oncogene Research Products OP09), Caspase-3 (Cell Signaling #9665), Alexa Flour 546 
donkey anti-rabbit (Life Technologies A10040), and Alexa Flour 647 goat anti-mouse (Life 
Technologies A21240). Confocal micrographs were taken using the FV1000 Confocal Laser 
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Scanning Microscope (Olympus) with a UPLFLN 40x Oil, N.A. 1.3 lens. 
Electrophoretic mobility shift assay  
Nuclear proteins were extracted from Mel-39 and A375 cells using the Nuclear Extract Kit 
(Active Motif) according to the manufacturer’s instructions. All oligonucleotide sequences used 
for the EMSA analysis are: TSS3151 SP1 Forward EMSA Biotin 5’-
/5Biosg/GCAGTGGGGTGGGGTTTGGA-3 and TSS3151 SP1 Reverse EMSA Biotin 5’-
/5Biosg/ TCCAAA CCCCACCCCACTGC-3. For EMSA, the Thermo Scientific LightShift 
Chemiluminescent EMSA Kit (Pierce/Thermo Fisher Scientific) was used according to the 
manufacturer’s instructions. Antibodies used were NF-B p65 (#sc-71677, Santa Cruz), SP1 
(#sc-59, Santa Cruz). 
Statistical methods 
Data were represented as mean ±standard deviation (s.d.) of at least three independent 
experiments, unless otherwise indicated, and analyzed by the two-tailed or one-tailed Student’s t-
test. The means and s.d. were calculated and displayed in bar graphs as the height and the 
corresponding error bar, respectively. A P < 0.05 was considered statistically significant.  
  
Undergraduate Research Thesis – Malori A. Lankenau 
 
36 
References 
1) "Surveillance, Epidemiology, and End Results ProgramTurning Cancer Data Into 
Discovery." Melanoma of the Skin. National Cancer Institute, n.d. Web. 10 Mar. 2015. 
2) "Skin Cancer Foundation." Melanoma. Skin Cancer Foundation, n.d. Web. 11 Feb. 2015. 
3) "New York Thyroid Center." Papillary Thyroid Cancer. Columbia University Department of 
Surgery, n.d. Web. 12 Mar. 2015. 
4) "BRAF Gene." Genetics Home Reference. N.p., Dec. 2012. Web. 12 Mar. 2015. 
5) Groussin, Lionel, and James A. Fagin. "Significance of BRAF Mutations in Papillary 
Thyroid Carcinoma: Prognostic and Therapeutic Implications." Nat Clin Pract Endocrinol 
Metab 2.4 (2006): 180-81. Medscape. Nature Publishing Group. Web. 12 Mar. 2015. 
6) Davies, H, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949–954. 
7) Melck, Adrienne L., Linwah Yip, and Sally E. Carty. "The Utility of BRAF Testing in the 
Management of Papillary Thyroid Cancer." The Oncologist 2010;15(12): 1285-293. 
8) Lito, P, Rosen, N, Solit, DB. Tumor adaptation and resistance to RAF inhibitors. Nat Med 
2013; 19:1401-9. 
9) Houben, R, Hesbacher S, Schmid CP, Kauczok CS, Flohr U, Haferkamp S, et. al. High-level 
expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 
reporter gene assays. PLoS ONE 2011;6: 1-7.  
10) Box, NF, Vukmer, TO and Terzian, T, Targeting p53 in melanoma. Pigment Cell & 
Melanoma Research 2013;27:8-10. 
11) Yu H, McDaid R, Lee J, Possik P, Li L, Kumar SM, et al. The role of BRAF mutation and 
Undergraduate Research Thesis – Malori A. Lankenau 
 
37 
p53 inactivation during transformation of a subpopulation of primary human melanocytes. 
Am J Path 2009;174:2367-2377. 
12) Malaguarnera, R., V. Vella, R. Vigneri, and F. Frasca. "P53 Family Proteins in Thyroid 
Cancer." Endocrine-Related Cancer 14 (2007): 43-60. Web. 
13) "Tumor Grade." National Cancer Institute. N.p., 3 May 2013. Web. 12 Mar. 2015. 
14) Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 
116:281-297.  
15) Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6:857 866, 
2006 
16) Calin GA, Croce CM: MicroRNA-cancer connection: The beginning of a new tale. Cancer 
Res 66:7390-7394, 2006 
17) Marcucci G, Radmacher MD, Maharry K, et al. MicroRNA expression in cytogenetically 
normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1919-1928.  
18) Garzon R, Volinia S, Liu C-G, et al. MicroRNA signatures associated with cytogenetics and 
prognosis in acute myeloid leukemia. Blood. 2008;111(6):3183-3189.  
19) Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian 
microRNA host genes and transcription units. Genome Res. 2004;14(10a):1902-1910.  
20) Griffiths-Jones S. Annotating noncoding RNA genes. Annu Rev Genomics Hum Genet. 
2007;8:279-298.  
21) Baskerville S, Bartel DP. Microarray profiling of microRNAs reveals frequent coexpression 
with neighboring miRNAs and host genes. RNA. 2005;11:241–247 
22)   Kim YK, Kim VN Processing of intronic microRNAs. EMBO 2007; J 26:775–783 
Undergraduate Research Thesis – Malori A. Lankenau 
 
38 
23)  Wang X, Xuan Z, Zhao X, Li Y, Zhang MQ. High-resolution human core-promoter 
prediction with CoreBoost_HM. Genome Res. 2009;19:266–275 
24) Corcoran DL, Pandit KV, Gordon B, Bhattacharjee A, Kaminski N, Benos PV. Features of 
mammalian microRNA promoters emerge from polymerase II chromatin 
immunoprecipitation data. PLoS One. 2009;4(4):e5279. Epub 2009 Apr 23. 
25) Monteys AM, Spengler RM, Wan J, Tecedor L, Lennox KA, Xing Y, Davidson BL. 
Structure and activity of putative intronic miRNA promoters.RNA. 2010 Mar;16(3):495-505. 
Epub 2010 Jan 14 
26) Najafi-Shoushtari SH, Kristo F, Li Y, et al. MicroRNA-33 and the SREBP host genes 
cooperate to control cholesterol homeostasis. Science. 2010;328(5985):1566-1569. 
27) Rayner KJ, Suárez Y, Dávalos A, Parathath S, Fitzgerald ML, Tamehiro N, Fisher EA, 
Moore KJ, Fernández-Hernando C., MiR-33 contributes to the regulation of cholesterol 
homeostasis. Science. 2010 Jun 18;328(5985):1570-3. 
28) Barik S. et al. An intronic microRNA silences genes that are functionally antagonistic to its 
host gene. Nucleic Acids Res. 2008 Sep;36(16):5232-41 
29) Veronese A, Lupini L, Consiglio J, Visone R, Ferracin M, Fornari F, Zanesi N, Alder H, 
D'Elia G, Gramantieri L, Bolondi L, Lanza G, Querzoli P, Angioni A, Croce CM, Negrini M. 
Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res. 2010 Apr 15;70(8):3140-
9. 
30)  Eisfeld AK, Schwind S, Patel R, Huang X, Santhanam R, Walker CJ, et al. Intronic miR-
3151 hosted by BAALC drives leukemogenesis by direct deregulation of the TP53 pathway. 
Science Signaling 2014;7:1-21.  
31)  Eisfeld AK, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, et al. miR-
Undergraduate Research Thesis – Malori A. Lankenau 
 
39 
3151 interplays with its host gene BAALC and independently impacts on outcome of patients 
with cytogenetically normal acute myeloid leukemia. Blood 2012;120:249-58. 
32)  Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, et al. Influence of BRAF V600E 
mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J 
Clin Endocr Metab 2006; 91:3667-3670. 
33)  Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, et al. Association 
between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. 
JAMA 2013; 309:1493-1501. 
34)  Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, et al. BRAF mutation 
predicts sensitivity to MEK inhibition. Nature 2006; 439:358-362. 
35) "FDA Approval for Vemurafenib." National Cancer Institute. N.p., 3 July 2013. Web. 12 
Mar. 2015. 
36)  Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved 
survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 
364:2507-2516. 
37)  Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in 
BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 
366:707-714. 
38)  Lee SK, Calin GA. Non-coding RNAs and cancer: new paradigms in oncology. Discov Med 
2011; 11:245-54. 
39)  Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol 2014; 9:287-
314. 
40)  Mueller DW, Bosserhoff AK. The evolving concept of “melano-miRs”-microRNAs in 
Undergraduate Research Thesis – Malori A. Lankenau 
 
40 
melanomagenesis. Pigment Cell Melanoma Res 2010; 23:620-6. 
41)  Monroig PD, Chen L, Zhang S, Calin GA. Small molecule compounds targeting miRNAs 
for cancer therapy. Adv Drug Deliv Rev 2014; pii:S0169-409X(14)00200-0. 
42)  Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. 
Nat Rev Drug Discov 2014; 13:622-38. 
43) "Apoptosis Signaling Pathway - @ a Glance." Abcam. N.p., n.d. Web. 12 Mar. 2015. 
  
Undergraduate Research Thesis – Malori A. Lankenau 
 
41 
Funding: This work was supported in part by the National Cancer Institute (grants P30 
CA16058, P01 CA124570), the Coleman Leukemia Research Foundation and the Pelotonia 
Fellowship Program.  
